When biologics should be used in systemic lupus erythematosus?

Gottenberg, Jacques-Éric; Lorenzo, Noel; Sordet, Christelle; Theulin, Arnaud; Chatelus, Emmanuel; Sibilia, Jean

doi:10.1016/j.lpm.2014.04.006

Cited by 5 publications

(4 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition to constant attempts to develop new molecules, works on identifying new targets for SLE therapy are equally intense [165]. Despite the above described failures, there has been a significant increase in the number of clinical trials conducted using innovative methods of treatment in patients with SLE in recent years.…”

Section: Discussionmentioning

confidence: 99%

Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review

Samotij

Reich

2019

BioMed Research International

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disease affecting multiple organ systems that runs an unpredictable course and may present with a wide variety of clinical manifestations. Advances in treatment over the last decades, such as use of corticosteroids and conventional immunosuppressive drugs, have improved life expectancy of SLE sufferers. Unfortunately, in many cases effective management of SLE is still related to severe drug-induced toxicity and contributes to organ function deterioration and infective complications, particularly among patients with refractory disease and/or lupus nephritis. Consequently, there is an unmet need for drugs with a better efficacy and safety profile. A range of different biologic agents have been proposed and subjected to clinical trials, particularly dedicated to this subset of patients whose disease is inadequately controlled by conventional treatment regimes. Unfortunately, most of these trials have given unsatisfactory results, with belimumab being the only targeted therapy approved for the treatment of SLE so far. Despite these pitfalls, several novel biologic agents targeting B cells, T cells, or cytokines are constantly being evaluated in clinical trials. It seems that they may enhance the therapeutic efficacy when combined with standard therapies. These efforts raise the hope that novel drugs for patients with refractory SLE may be available in the near future. This article reviews the current biological therapies being tested in the treatment of SLE.

show abstract

Section: Discussionmentioning

confidence: 99%

Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review

Samotij

Reich

2019

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…Belimumab is currently the only approved biologic for the treatment of SLE [Gottenberg et al 2014], its efficacy being demonstrated by two large phase III randomized studies, the BLISS-52 and BLISS-76 trials (Table 1) [Furie et al 2011; Navarra et al 2011].…”

Section: Slementioning

confidence: 99%

“…Other BAFF inhibitors currently being evaluated for SLE are blisibimod and tabalumab (Table 3) [Gottenberg et al 2014].…”

Section: Slementioning

confidence: 99%

B-cell survival factors in autoimmune rheumatic disorders

Morais

Vilas-Boas

Isenberg

2015

Therapeutic Advances in Musculoskeletal

View full text Add to dashboard Cite

Autoimmune rheumatic disorders have complex etiopathogenetic mechanisms in which B cells play a central role. The importance of factors stimulating B cells, notably the B-cell activating factor (BAFF) and A proliferation inducing ligand (APRIL) axis is now recognized. BAFF and APRIL are cytokines essential for B-cell proliferation and survival from the immature stages to the development of plasma cells. Their levels are increased in some subsets of patients with autoimmune disorders. Several recent biologic drugs have been developed to block this axis, namely belimumab [already licensed for systemic lupus erythematosus (SLE) treatment], tabalumab, atacicept and blisibimod. Many clinical trials to evaluate the safety and efficacy of these drugs in several autoimmune disorders are ongoing, or have been completed recently. This review updates the information on the use of biologic agents blocking BAFF/APRIL for patients with SLE, rheumatoid arthritis, Sjögren's syndrome and myositis.

show abstract

“…Belimumab is a monoclonal antibody against BAFF, and is currently the only approved biological for the treatment of SLE. 34 …”

Section: Belimumabmentioning

confidence: 99%

Belimumab in systemic lupus erythematosus

2015

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is one of the most challenging autoimmune disorders with a complex pathophysiology and diverse clinical presentation. Many drugs have been used to treat SLE with suboptimal results, especially in patients with moderate-to-severe disease. Belimumab is the first biological drug to be approved for the treatment of SLE in more than 50 years. This monoclonal antibody blocks B-cell activating factor, a cytokine important for B-cell differentiation and survival. In this review we focus on the activity of belimumab in patients with SLE and discuss the controversies of its use.

show abstract

When biologics should be used in systemic lupus erythematosus?

Cited by 5 publications

References 31 publications

Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review

Biologics in the Treatment of Lupus Erythematosus: A Critical Literature Review

B-cell survival factors in autoimmune rheumatic disorders

Belimumab in systemic lupus erythematosus

Contact Info

Product

Resources

About